1% organic sales growth y-o-y Profitability still at a good level Lower utilisation rather than drop...
Fortsatt utmanande för tillväxt Nettoomsättningen uppgick i kvartalet till 36,3 mkr vilket motsvarar...
Rapporten för det fjärde kvartalet kom in något bättre än Analysguidens förväntningar.
I torsdags den 8 februari 2024 meddelade Mindark PE en omvänd vinstvarning, dels till följd av juste...
Active Biotech flaggar för tre nya studier under 2024 samtidigt som den pågående studien inom multip...
Stark leverans från båda affärsområdena Omsättningen i kvartalet uppgick till EUR 35,6m, vilket mots...
Förtroendegivande avslutning på 2023 Senzagen presterade starkt i Q4(23) med en nettoomsättning som ...
Redeye comments on SDS’s Q4 results, which came in weaker than expected in terms of sales and profit...
Fastighetsservicebolaget rapporterade över Analysguidens förväntningar, både vad gäller nettoomsättn...
Net sales came in higher than expected. The sales, amounting to SEK69m, were more in line with our p...
Redeye saw a Q4 report that was again weaker than expected.
Redeye comments on Tessin’s Q4 results, which showed lower sales than expected due to limited capita...
Redeye provides its initial take on Mentice’s Q4 2023 report, which came in broadly below our estima...
Redeye has updated its estimates for Safeture following the Q4 2023 report.
Sales -6% and adj. EBIT SEK -1.5m vs. ABGSCe Growth driven by GC&MP and FW, while NW&FT underperform...
Redeye comments on Gasporox's Q4 report, which was in line with estimates.
Redeye will likely increase its forecasts and Base Case following a Q4 report showing stronger-than-...
Redeye comments on Carasent's Q4 2023 report, which came in in line on sales, but slightly lower on ...
Alisa Bank’s H2 profitability was slightly below our expectations, with PTP at EUR -0.
Raute’s Q4 figures were slightly mixed relative to our estimates as Services and Analyzers performed...
